MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Arvinas Holding Company, Inc. (NASDAQ: ARVN)*
Organization & Developments: Arvinas
Parents
Arvinas Holding Company, Inc. (NASDAQ: ARVN)*
Children
2019: Arvinas: Initial Clinical Data Provides Validation For PROTAC Platform_seekingalpha.com
2020: The pipeline is early stage, but robust, featuring no fewer than 13 programs in the fields of oncology, immune-oncology, and neuroscience.
2022: Arvinas (ARVN) Investor Presentation - Slideshow_ seekingalpha.com
2022: Arvinas: Promising Science, Poor Data_ seekingalpha.com
2023: Arvinas: Positive Breast Cancer Data Leads To Other Developments_seekingalpha.com
2023: Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity_seekingalpha.com
2023: Arvinas' Potential In Treating ER+, HER2- Breast Cancer
2024: Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation
2024: Arvinas: Behind The Huge Rally
2024: Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause
2024: Novartis Inks $1B Protein Degrader Deal with Arvinas, Begins MorphoSys Tender Offer
2024: Novartis pays $150M for Arvinas' phase 3-ready prostate cancer protein degrader
2025: Arvinas lays off 33% of staff, axes Pfizer-partnered phase 3 trials after seeing mixed data
2025: Arvinas: A Potential 'Sum Of The Parts' Story
2025: Arvinas' Breakthrough Breast Cancer Treatment
Jumps
Finance & Acquisitions: Arvinas
Key People: Arvinas